Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Frank D. Vrionis, MD, MPH, PhD
Moffitt Cancer Center
Principal Investigator - Philip J Bierman, MD
University of Nebraska
Principal Investigator - Ray M. Chu, MD
Cedars-Sinai Medical Center
Principal Investigator - Susan C. Pannullo, MD
New York Presbyterian - Cornell
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2008
- Primary completion
- 31 Aug 2013
- Completion
- 31 Dec 2013
- Last update posted
- 10 Feb 2011
- Registered enrollment
- 9
- Registry id
- NCT00615186
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.